Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.54 |
| ▸ | VDR | P11473 | 5/20 | 0.54 |
| ▸ | IDH1 | O75874 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511355 | 1.00 | L3MBTL1 (0.57) | L3MBTL1NR1H4VDRIDH1HSD17B10 | |
| SCHEMBL5518839 | 0.99 | L3MBTL1 (0.55) | L3MBTL1NR1H4VDRIDH1HSD17B10 | |
| SCHEMBL5519048 | 0.97 | L3MBTL1 (0.54) | L3MBTL1NR1H4VDRIDH1HSD17B10 | |
| SCHEMBL14382913 | 0.97 | NR1H4 (0.54) | L3MBTL1NR1H4VDRIDH1NR4A1 | |
| SCHEMBL14382681 | 0.95 | NR1H4 (0.53) | L3MBTL1NR1H4VDRIDH1NR4A1 | |
| SCHEMBL5526412 | 0.94 | L3MBTL1 (0.56) | L3MBTL1NR1H4VDRIDH1HSD17B10 | |
| SCHEMBL14382397 | 0.94 | NR1H4 (0.53) | L3MBTL1NR1H4VDRIDH1NR4A2 | |
| SCHEMBL5066585 | 0.93 | NR1H4 (0.54) | L3MBTL1NR1H4VDRIDH1HSD17B10 | |
| SCHEMBL12150498 | 0.93 | L3MBTL1 (0.50) | L3MBTL1NR1H4VDRIDH1MAPT | |
| SCHEMBL5517031 | 0.92 | L3MBTL1 (0.51) | L3MBTL1NR1H4VDRIDH1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | claimed |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-07-14 | — | — | US | claimed |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2004-05-20 | — | — | US | claimed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | claimed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | claimed |
| CN-1342145-A | fused ring compound and pharmaceutical use thereof | JAPAN TOBACCO INC (JP) | 2002-03-27 | — | — | CN | claimed |
| EP-1162196-A1 | FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS | JAPAN TOBACCO INC. (JP) | 2001-12-12 | — | — | EP | claimed |
| EP-3471737-B1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-12173025-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11752166-B2 | Combination therapy for treatment of HCV | COCRYSTAL PHARMA, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3790542-B1 | COMBINATION THERAPY FOR TREATMENT OF HCV | COCRYSTAL PHARMA INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | PRIESTLEY ELDON SCOTT (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-17 | — | — | US | disclosed |
| WO-2003026587-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
| EP-1162196-A1 | FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS | JAPAN TOBACCO INC. (JP) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | EIF2AK2, MAVS, NSUN3 | L3MBTL1 1314/4885NR1H4 2462/4885VDR 3893/4885 |
| US-11752166-B2 | Combination therapy for treatment of HCV | HAVCR2, EIF2AK2, SERPINB1 | L3MBTL1 3257/4885NR1H4 220/4885VDR 3261/4885 |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | L3MBTL1 3799/4885NR1H4 484/4885VDR 3852/4885 |
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | OAT, HAVCR2, GOT1 | L3MBTL1 1110/4885NR1H4 12/4885VDR 858/4885 |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | L3MBTL1 4672/4885NR1H4 37/4885VDR 3966/4885 |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, SLC10A1 | L3MBTL1 4548/4885NR1H4 20/4885VDR 4266/4885 |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | EIF2AK2, MAVS, NSUN3 | L3MBTL1 1314/4885NR1H4 2462/4885VDR 3893/4885 |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | ACE, SARS1, EIF2AK2 | L3MBTL1 1230/4885NR1H4 1952/4885VDR 2313/4885 |
| US-12173025-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | L3MBTL1 1351/4885NR1H4 1291/4885VDR 1900/4885 |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | OAT, HAVCR2, GOT1 | L3MBTL1 1110/4885NR1H4 12/4885VDR 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.